The present invention relates to pharmaceutical formulations comprising specific hydrazidomycin compounds. Since said hydrazidomycin compounds show cytotoxic activities, the present invention further relates to said hydrazidomycin compounds for use in medicine, in particular in the treatment of proliferative disorders.